Abstract
Motor cortex stimulation (MCS) has been used in the treatment of intractable neuropathic facial pain for nearly 30 years. While efficacy rates have been noted as high as 88% in some studies, considerable variability in treatment response remains. Additionally, MCS is often cited as providing diminishing relief over time, and there are few long-term studies on efficacy. Complications are generally mild and include infection, hardware complication, seizure, and transient neurological deficit. Despite relatively minimal use, MCS remains a viable treatment option for the appropriately selected facial pain patients that have proved refractory to conservative management.
Original language | English (US) |
---|---|
Pages (from-to) | 162-169 |
Number of pages | 8 |
Journal | Progress in Neurological Surgery |
Volume | 35 |
DOIs | |
State | Published - 2020 |
ASJC Scopus subject areas
- Surgery
- Clinical Neurology